IDEXX Laboratories’ Q3 earnings have renewed attention on its premium valuation. But the supplied information doesn’t include the quarter’s results or guidance, so investors can’t assess how the performance compares with the company’s valuation. IDEXX shares last closed at US$693.98, with a reported P/E of 38.7.
Investor takeaway: The Q3 earnings headline raises a valuation question, but the available facts don’t include the results needed to answer it.
IDEXX closed at US$693.98 with a reported P/E of 38.7
IDEXX Laboratories Inc
IDXX.US
IDXX.US
IDEXX Laboratories Inc
WealthAwesomeMarket cap
$52.91B
P/E
38.7x
52W high
$769.98
52W low
$500.61
1W change
+19.74%
Beta
1.54
Analyst Price Targets
Based on 14 analysts covering IDXX · as of Nov 3, 2026
Wall Street analysts forecast IDXX stock price to rise 3.4% over the next 12 months.
Consensus
Buy3.93 / 5.00
Avg. Target
C$694.83
+3.4% Upside
Previously C$694.42 on Oct 29, 2026
Current Price
C$672.04
Last close
Analyst Breakdown (14 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on IDXX's historical volatility
30-Day Vol
62.9%
Annualized
90-Day Vol
43.4%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$803.43
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$713.26 | C$574.02 – C$886.27 |
| 60 trading days | C$757.00 | C$556.81 – C$1029.17 |
| 90 trading days | C$803.43 | C$551.54 – C$1170.35 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
The P/E is the clearest figure tied to the valuation discussion. Without Q3 results, there’s no basis here to compare the multiple with the company’s quarterly performance.
Bull case
The supplied company data show a 25.0% profit margin and 74.2% return on equity.
Bear case
A P/E of 38.7 puts the valuation in focus, but the supplied information doesn’t include Q3 results or guidance to assess against it.
Q3 earnings headline raises a valuation question
A Nov. 3 headline says IDEXX Laboratories’ Q3 earnings have put its premium valuation in focus. It doesn’t give quarterly revenue, earnings per share, or management guidance. A separate headline, citing UBS, says the company delivered results despite a lacklustre veterinary-visit backdrop. That recap doesn’t include the underlying figures either.
The available information confirms the earnings event and the valuation theme, but not how the quarter measured up. Investors can visit the IDEXX stock page, though the supplied data don’t include the missing earnings details.
Price and valuation figures provide context, not an earnings comparison
IDEXX last closed at US$693.98. Its reported P/E was 38.7336, market capitalization was about US$52.9 billion, and trailing-twelve-month EPS was US$17.34. The company also reported a 25.0% profit margin and 74.2% return on equity.
These figures provide context for the valuation discussion, but they aren’t Q3 results and don’t show whether the quarter justified the multiple. Latest trading volume was 300,577 shares, compared with a 20-day average of 629,211. The shares rose 0.06% that day and 19.74% over one week, according to the supplied data. Those figures don’t explain the earnings or what drove the share-price moves.
The missing Q3 figures are the key next detail
The next details investors need are Q3 revenue, earnings, and any guidance. None appears in the supplied information. Those figures would help investors assess the quarter alongside the reported P/E and other company metrics.
The headline also doesn’t explain why the valuation is considered premium or compare it with peers or IDEXX’s own history. Without that context, this remains a valuation-focused earnings headline, not a complete account of the quarter. More company information is available on the IDEXX stock page, but the supplied facts don’t include further Q3 disclosures.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
